Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Lin, Gloria H Y ^a   Liu, Yuanqing ^a   Ambagala, Thanuja ^a   Kwon, Byoung S ^b,d   Ohashi, Pamela S ^c   Watts, Tania H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b National Cancer Center   (South Korea)

^c Princess Margaret Cancer Center   (Canada)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 1BB PROTEIN ANTIBODY; CD137 ANTIGEN; CD69 ANTIGEN; HERMES ANTIGEN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; THYMOMA; TUMOR REGRESSION; TUMOR REJECTION;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; CD8-POSITIVE T-LYMPHOCYTES; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; MICE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, TUMOR NECROSIS FACTOR;

MUS;

EID: 77956214554     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011003     Document Type: Article

References (63)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
2. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476.
3. Hurtado JC, Kim YJ, Kwon BS (1997) Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. Journal of Immunology 158: 2600-2609.
4. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, et al. (2002) 4-1BB Promotes the Survival of CD8(+) T Lymphocytes by Increasing Expression of Bcl-x(L) and Bfl-1. J Immunol 169: 4882-4888.
5. Lin GH, Sedgmen BJ, Moraes TJ, Snell LM, Topham DJ, et al. (2009) Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol 182: 934-947.
6. Pulle G, Vidric, M, Watts, H T (2006) IL-15-dependent induction of 4-1BB promotes Ag-independent CD8 memory T cell survival. J Immunol 176: 2739-2748.
7. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, et al. (1997) 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. Journal of Experimental Medicine 186: 47-55.
8. Takahashi C, Mittler RS, Vella AT (1999) Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. Journal of Immunology 162: 5037-5040.
9. Zhu Y, Zhu G, Luo L, Flies AS, Chen L (2007) CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109: 4882-4889.
10. Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, et al. (2007) 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 179: 4910-4918.
11. Bukczynski J, Wen T, Ellefsen K, Gauldie J, Watts TH (2004) Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A 101: 1291-1296.
12. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, et al. (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Medicine 3: 682-685.
13. Cheuk AT, Mufti GJ, Guinn BA (2004) Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 11: 215-226.
14. Lynch DH (2008) The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 222: 277-286.
15. Ehrenstein MR, Mauri C (2007) If the treatment works, do we need to know why? the promise of immunotherapy for experimental medicine. J Exp Med 204: 2249-2252.
16. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
17. Klebanoff CA, Yu Z, Hwang LN, Palmer DC, Gattinoni L, et al. (2009) Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood 114: 1776-1783.
18. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626.
19. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, et al. (2005) Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 102: 9571-9576.
20. Klebanoff CA, Gattinoni L, Restifo NP (2006) CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211: 214-224.
21. Rolle CE, Carrio R, Malek TR (2008) Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy. Cancer Res 68: 2984-2992.
22. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, et al. (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173: 7125-7130.
23. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, et al. (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118: 294-305.
24. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L (1998) NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cellular Immunology 190: 167-172.
25. Martinet O, Ermekova V, Qiao JQ, Sauter B, Mandeli J, et al. (2000) Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. J Natl Cancer Inst 92: 931-936.
26. Ito F, Li Q, Shreiner AB, Okuyama R, Jure-Kunkel MN, et al. (2004) Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 64: 8411-8419.
27. Li Q, Iuchi T, Jure-Kunkel MN, Chang AE (2007) Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci 3: 455-462.
28. Murillo O, Dubrot J, Palazon A, Arina A, Azpilikueta A, et al. (2009) In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 39: 2424-2436.
29. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, et al. (2009) Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 114: 3431-3438.
30. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, et al. (2007) Cytokine-Mediated Disruption of Lymphocyte Trafficking, Hemopoiesis, and Induction of Lymphopenia, Anemia, and Thrombocytopenia in Anti-CD137-Treated Mice. J Immunol 178: 4194-4213.
31. Gorak-Stolinska P, Truman JP, Kemeny DM, Noble A (2001) Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha. J Leukoc Biol 70: 756-766.
32. Spaner D, Raju K, Radvanyi L, Lin Y, Miller RG (1998) A role for perforin in activation-induced cell death. J Immunol 160: 2655-2664.
33. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
34. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM (1989) Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342: 559-561.
35. Kaech SM, Ahmed R (2001) Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2: 415-422.
36. Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, et al. (2000) Early programming of T cell populations responding to bacterial infection. J Immunol 165: 6833-6839.
37. van Stipdonk MJ, Lemmens EE, Schoenberger SP (2001) Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2: 423-429.
38. Miller RE, Jones J, Le T, Whitmore J, Boiani N, et al. (2002) 4-1BB-specific monoclonal antibody promotes the generation of tumor- specific immune responses by direct activation of CD8 T cells in a CD40- dependent manner. J Immunol 169: 1792-1800.
39. Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, et al. (2002) Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 14: 275-286.
40. Wilcox RA, Chapoval AI, Gorski KS, Otsuji M, Shin T, et al. (2002) Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol 168: 4262-4267.
41. Wilcox RA, Tamada K, Strome SE, Chen L (2002) Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 169: 4230-4236.
42. Choi BK, Kim YH, Kwon PM, Lee SC, Kang SW, et al. (2009) 4-1BB functions as a survival factor in dendritic cells. J Immunol 182: 4107-4115.
43. Hermans IF, Daish A, Yang J, Ritchie DS, Ronchese F (1998) Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res 58: 3909-3917.
44. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, et al. (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064.
45. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
46. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, et al. (2009) Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 106: 17469-17474.
47. Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med 207: 223-235, S221-224.
48. Xu D, Gu P, Pan PY, Li Q, Sato AI, et al. (2004) NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 109: 499-506.
49. Pan PY, Gu P, Li Q, Xu D, Weber K, et al. (2004) Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol 172: 4779-4789.
50. Tammana S, Huang X, Wong M, Milone MC, Ma L, et al. (2009) 4-1BB and CD28 Signaling Plays A Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies. Hum Gene Ther.
51. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, et al. (2009) A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183: 5563-5574.
52. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, et al. (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17: 1453-1464.
53. Narazaki H, Zhu Y, Luo L, Zhu G, Chen L. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 115: 1941-1948.
54. Myers L, Lee SW, Rossi RJ, Lefrancois L, Kwon BS, et al. (2006) Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol 18: 325-333.
55. Dubrot J, Milheiro F, Alfaro C, Palazon A, Martinez-Forero I, et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother.
56. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, et al. (2007) T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13: 1440-1449.
57. Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, et al. (2009) A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine 28: 512-522.
58. Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, et al. (2009) Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 69: 4319-4326.
59. Kwon BS, Hurtado JC, Lee ZH, Kwack KB, Seo SK, et al. (2002) Immune responses in 4-1BB (CD137)-deficient mice. J Immunol 168: 5483-5490.
60. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, et al. (1994) T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
61. Carrio R, Bathe OF, Malek TR (2004) Initial antigen encounter programs CD8+ T cells competent to develop into memory cells that are activated in an antigen-free, IL-7- and IL-15-rich environment. J Immunol 172: 7315-7323.
62. Manjunath N, Shankar P, Wan J, Weninger W, Crowley MA, et al. (2001) Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest 108: 871-878.
63. Bertram EM, Lau P, Watts TH (2002) Temporal segregation of CD28 versus 4-1BBL-mediated costimulation: 4-1BBL influences T cell numbers late in the primary response and regulates the size of the memory response following influenza infection. Journal of Immunology 168: 3777-3785.